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Germline mutations of the LKB1/STK11 gene, a serine threonine
kinase, on 19p13.3 have been shown to account for the majority of
Peutz-Jeghers Syndrome (PJS, OMIM 175200) cases (Hemminki
et al, 1998). Nevertheless, up to 50% of PJS cases have no
detectable  LKB1 mutation and families unlinked to 19p13.3 have
been reported (Olschwang et al, 1998). PJS patients develop
hamartomas at many sites including the gastrointestinal tract, and
the polyps have an arborizing structure with a smooth muscle core. 
Hamartomas of the GI tract are the main characteristic of
Juvenile Polyposis Syndrome (JPS, OMIM 174900), but the
polyps differ from those in PJS: the juvenile polyps do not have
the characteristic smooth muscle core of PJS polyps, have a
greater inflammatory component, and have expanded mucin-filled
cysts. Germline mutations of the SMAD4/DPC4 gene, a down-
stream regulator in the TGFb signalling pathway, on 18q21.1,
cause JPS, but can only account for about 20–25% of JPS cases
(Houlston et al, 1998; Howe et al, 1998). The SMAD4 gene has
been shown to act as a tumour suppressor gene not only in JPS
(Woodford-Richens et al, 2000) but also in sporadic colon and
pancreatic cancers (Thiagalingam et al, 1996; Hahn, 1996 #435).
Therefore, it seems likely that genes which may be considered as
good candidates for the remaining PJS and JPS cases are those
which are involved as part of the stepwise progression of
colorectal cancer. 
The caudal-type homeobox gene, CDX2 (Genbank accession
numbers AF00384/5/6), encodes a transcription factor which is
expressed in the intestine, and is thought to play a role in the
differentiation and proliferation of intestinal epithelial cells
(Drummond et al, 1997; Lorentz et al, 1997). Mice heterozygous
for CDX2 null mutations give rise to a phenotype that includes
colonic polyps reported to have features of hamartomas
(Chawengsaksophak et al, 1997; Tamai et al, 1999). These hamar-
tomas do not express CDX2, indicating that biallelic inactivation
of the CDX2 gene is probably an important step for the growth of
hamartomas (Tamai et al, 1999). CDX2 has also been implicated in
the development and progression of a subset of human colorectal
cancers (da Costa et al, 1999; Mallo et al, 1997; Yagi et al, 1999). 
Taken together, these findings indicate that the CDX2 gene may
be a good candidate for those cases of PJS and JPS who are not
explained by mutations in LKB1 or SMAD4. We have therefore
screened the CDX2 gene for germline mutations in 37 JPS patients
and 10 PJS patients without known SMAD4 or LKB1 mutations,
and for somatic mutations in 49 sporadic colorectal cancers. 
PATIENTS AND METHODS 
Patients were selected who had JPS (five or more juvenile polyps
or any number of juvenile polyps and a family history of JPS, plus
no clinical features suggestive of other hamartoma syndromes
such as Cowden, Gorlin or Bannayan-Zonana syndromes) or PJS
(characteristic hamartomas of gastrointestinal tract and classical
pigmentation of the lips and buccal mucosa, or with only one 
of these features in a familial context). Each patient had been
screened previously for either SMAD4 (JPS) or LKB1 (PJS)
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Houlston et al, 1998; Ylikorkala et al, 1999). Also chosen for
screening were 49 colorectal cancer cell lines (C10, C32, C70,
C75, C80, C84, C99, C106, C125, CAC02, COLO201, COLO205,
COLO206, COLO320, COLO678, COLO741, CX1, DLD1,
GP2D, GP5D, HCA46, HCA7, HCT8, HCT15, HCT116, HRA19,
HT29, HT55, LIM1863, LOVO, LS174T, LS180, LS411, LS1034,
PC/JW, SKC01, SW48, SW403, SW480, SW620, SW837,
SW948, SW1222, SW1417, T84, VACO4A, VACO4S, VACO5,
VACO10). Control samples were derived from an unselected UK
population with no known cancer predisposition, but were not
matched for age or sex. DNA was extracted from peripheral blood
lymphocytes and cell lines using standard methods. 
PCR primers for exon-by-exon amplification of CDX2 from
genomic DNA (Genbank accession numbers AF00384/5/6) were
designed using Primer3 (http://www-genome.wi.mit.edu/cgi-
bin/primer/primer3_www.cgi), with the forward and reverse
primers both fluorescently dye-labelled (FAM, TET or HEX).
PCRs were performed according to the conditions shown (Table 1),
and then diluted 1:50 with distilled water. After combining the
fluorescent PCR products with an internal size standard (Tamra
350, PE Applied Biosystems, Warrington, UK) and formamide, F-
SSCP analysis was performed using an ABI310 sequencer (PE
Applied Biosystems, Warrington, UK), under two different
temperature conditions (20˚C and 35˚C). PCR products were also
screened for mutations causing conformational change using the
PHAST mini-gel SSCP system at 10˚C according to manufac-
turer’s instructions, again using different temperature conditions
(Pharmacia, Uppsala, Sweden). 
Fragments showing both aberrant and normal migration were
re-amplified using non-fluorescently labelled primers, purified
using Qiaquick columns (Qiagen, Hilden, Germany) and then
sequenced in both forward and reverse orientations using the ABI
Big Dye Terminator kit (PE Applied Biosystems, Warrington,
UK). Sequencing was performed on a subset of samples (at least
10) with normal SSCP bands to ensure all mutations were
detected. No mutations were detected by direct sequencing that
were not detected by F-SSCP. 
RESULTS AND DISCUSSION 
No pathogenic mutations of CDX2 were found in the 37 JPS cases or
in the 49 colorectal cell lines. One of the 10 PJS cases showed aber-
rant migration for CDX2 exon 3 on SSCP, which upon sequencing
showed an A to T base change at nucleotide 941. This change lies in
the 3¢ untranslated region of the CDX2 gene upstream of the poly A
signal, and is not conserved in the mouse CDX2 mRNA (Genbank
NM007673). The mutation was not observed in any of the JPS
cases, colon cancer cell lines or 100 normal control chromosomes,
but its significance must remain doubtful. 
A missense polymorphism was detected in exon 3, a TCT to
CCT transition at nucleotide 871 which introduces a serine to
proline amino acid change at codon 291. Although this might be a
potential phosphorylation site, sequence analysis programs detect
no evidence of homology to any consensus sequence (details not
shown). Mouse Cdx2 has a proline residue at codon 291 and is not
known to be polymorphic. The frequencies of the serine and
proline alleles were not significantly different in the JPS or PJS
patients, in the cancer cell lines from the frequencies in a UK
control cohort (Table 2) or from those frequencies previously
reported in colorectal cancer (Yagi et al, 1999) (data not shown).
These data therefore confirm previous suggestions that S291P is a
polymorphism (Wicking et al, 1998), which is not functionally
significant for JPS or PJS, although some potential functional
significance as a low-penetrance cancer predisposition allele
cannot entirely be excluded. 
The previously reported silent polymorphism at codon 61, a
CCG to CCC change (Yagi et al, 1999), was not detected in our
study using SSCP, or by direct sequencing of 10 of the cancer cell
line DNAs. This may result from population differences between
studies. However, being a silent polymorphism the nucleotide
change was anticipated not to produce any functional effect. 
Thus, despite the Cdx2 mouse knockout developing colonic
hamartomas which makes CDX2 a good candidate for JPS and
PJS, we have shown that germline CDX2 mutations do not account
for the development of these two hamartoma syndromes. We have
assessed linkage to the CDX2 region (13q12.3) in the familial JPS
CDX2 in JPS, PJS and colorectal cancer 1315
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Table 1 Primers and PCR conditions for CDX2. Exon 1 is divided into three parts so suitable fragments size for SSCP were obtained. ‘Temp’ indicates the
annealing temperature of the PCR reaction and ‘Mg2+’ shows Mg2+ concentration required 
Exon Forward primer Reverse primer Temp.(˚C) Mg2+ (mM) 
1 part 1 CAGCATGGTGAGGTCTGCT GCGTAGCCATTCCAGTCCT  55 0.5 
1 part 2 GGCAGCGAACTTGGACAG GTTGAGCGTTTGCAGCAG  55 1 
1 part 3 AGCCCCGCAGACTACCAT CGCAGCCTCTGCTTACCTT  55 0.5 
2 GCCCTCACTTCTCCTTCCTC GTCCCCACCTGCCTCTCA 65 2.5 
3 TTTTCTCCACCTTTCCATTTC TCAGCCTGGAATTGCTCTG 55 2.5 
Table 2 Frequencies of the polymorphic CDX2 exon 3 alleles in JPS, PJS, colorectal cancer cell lines and a control cohort. The observed
frequencies of the respective alleles did not differ significantly between patients and controls (Fisher’s exact test, P > 0.3). The genotype
frequencies do not differ significantly from Hardy–Weinberg equilibrium in any case (details not shown) 
Patients Frequency of (t/t) homozygotes (%)  Frequency of (c/t) heterozygotes (%) Frequency of (c/c) homozygotes (%) 
Juvenile polyposis 68 (25/37) 30 (11/37) 2 (1/37) 
Peutz–Jeghers 80 (8/10) 20 (2/10) 0 (0/10) 
CRC cell lines 72 (35/49) 22 (11/49) 6 (3/49) 
Controls 78 (40/51) 22 (11/51) 0 (0/51) 1316 KL Woodford-Richens et al 
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cases and found no evidence of linkage to this region, again
sustaining that CDX2 is probably not important in JPS or PJS (data
not shown). The one PJS patient who possessed an A to T trans-
version in the 3¢ UTR is unlikely to have their disease attributable
to this sequence variant – unless the change contributes directly to
mRNA stability or splicing in some unknown fashion. One
possible way of determining the role of this variant would be to
look for a ‘second hit’ – that is, biallelic inactivation of CDX2 – in
the hamartomas of this patient, but no such material was available.
It has been suggested that the hamartomas in the knockout mouse
resemble heterotopias or intercalations, that is reduplication of gut
tissue in the colon, rather than true hamartomas (Beck et al, 1999).
If so, it may therefore be unsurprising that no pathogenic muta-
tions were found in two human syndromes where true hamartomas
are present. 
We have also shown that none of 49 colorectal cancer cell lines
possesses a pathogenic mutation of CDX2. Previous reports have
all found a low frequency of CDX2 mutations in colon cancers (da
Costa et al, 1999; Yagi et al, 1999). In one study, a single colon
cancer showed biallelic inactivation of CDX2 and restoration of
expression inhibited growth (Wicking et al, 1998). Overall, it
seems unlikely that somatic CDX2 mutations are an important step
in the pathogenesis of colorectal cancer. However, gene inactiva-
tion or silencing of CDX2 via promoter methylation and/or loss of
heterozygosity has not been ruled out and further investigation is
required to ascertain whether this gene has an important role in the
development of colorectal malignancies. 
The genetic aberrations which are responsible for cases of PJS
and JPS not caused by the LKB1 and SMAD4 genes respectively,
remain elusive. Although there is debate regarding the existence of
a second PJS locus, there is convincing evidence of at least one
additional JPS locus. Further screening of candidate genes may be
necessary to discover this gene, since the alternative – linkage
analysis – will be problematic: most JPS families are too small to
exclude SMAD4 linkage and the existence of families with unde-
tectable SMAD4 mutations may confound the detection of critical
recombinants. 
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